Evidence map›Paper›PMID 22867736›Full record

ArticleGynecologic oncology2012

Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence.

J J Wallbillich, H E Rhodes, A M Milbourne, M F Munsell, M Frumovitz, J Brown, C L Trimble, K M Schmeler

Open access · greenAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Gynecologic oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Medical interventions for high-grade vulval intraepithelial neoplasia.The Cochrane database of systematic reviews · 2015
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. COInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Article
  7. Article
  8. Article
  9. Vulval premalignant lesions: a review article.Obstetrics & gynecology science · 2024
    Article
  10. Article
  11. Article
  12. Treatment of vulvar and vaginal dysplasia: plasma energy ablation versus carbon dioxide laser ablation.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2021
    Article
  13. Article
  14. Epidemiology of HPV Related Malignancies.Seminars in radiation oncology · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

J J WallbillichDepartment of Obstetrics, Gynecology, and Reproductive Sciences, The University of Texas Health Science Center at Houston, USA.
H E Rhodes
A M Milbourne
M F Munsell
M Frumovitz
J Brown
C L Trimble
K M Schmeler
The University of Texas MD Anderson Cancer Center · USJohns Hopkins University · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Mechanisms of mucosal immune evasion in high grade cervical dysplasiaR01CA142691 · NCI · JOHNS HOPKINS UNIVERSITY · PI TRIMBLE, CORNELIA L · 2010 to 2014
$1.3M
NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA142691
6 · The paper itself

Abstract

objectiveTo evaluate demographic and clinical characteristics associated with the development of vulvar intraepithelial neoplasia (VIN 2/3), and factors associated with recurrence.

methodsA retrospective chart review of 303 patients with VIN 2/3 evaluated at a single institution between 1993 and 2011 was performed. Medical records were reviewed for demographic information, risk factors, treatment type, pathologic diagnosis, and recurrence/outcome information.

resultsMedian age at diagnosis was 47 years (range 14-87). 40% of patients reported current tobacco use and 26% reported previous use. Primary treatment included excision (n=176, 59%), laser ablation (n=40, 13%), imiquimod (n=22, 7.4%), excision with laser (n=24, 8.1%), excision with imiquimod (n=10, 3.4%), and laser with imiquimod (n=3, 1.0%). 92 patients (62.6%) were noted to have positive margins, which was associated with larger tumor size (p=0.004). 87 patients (28.7%) developed recurrent disease, which was associated with smoking (p<0.001), larger lesion size (p=0.016), and positive margins (p=0.005). On univariate analysis, higher rates of recurrence were associated with laser ablation (45.0%) compared with excision (26%) or imiquimod (13.6%) (p=0.018). However, on multivariate analysis of recurrence-free survival (RFS) these therapies were equivalent when used individually, but the use of excision plus laser had an adverse impact on RFS (p<0.001). 7 patients (2.3%) recurred with invasive disease a median of 109 months (range 12-327) from initial VIN 2/3 diagnosis.

conclusionsThis large cohort of women with VIN 2/3 further delineates the demographic and clinical factors associated with VIN 2/3. High rates of recurrence were noted and found to be associated with smoking, larger lesion size, and positive margins. While higher rates of recurrence were found among those treated with laser ablation, it was not inferior with respect to RFS when used alone, but the use of laser with excision was associated with decreased RFS. Our findings provide hypothesis-generating material for further research in the management of VIN2/3.

Indexed as

Laser TherapyAdolescentAdultAgedAged, 80 and overAminoquinolinesAntineoplastic AgentsCarcinoma in SituCombined Modality TherapyFemaleHumansImiquimodMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingAminoquinolinesAntineoplastic AgentsImiquimod

Identifiers

PMID22867736
PMCPMC3632361
OpenAlexW2134371077

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.